Heregulin ameliorates the dystrophic phenotype in mdx mice.
about
Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscleDrug treatment of Duchenne muscular dystrophy: available evidence and perspectivesIRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cellsDrug discovery for Duchenne muscular dystrophy via utrophin promoter activation screeningDaily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouseTranslational regulation of utrophin by miRNAsEts-2 repressor factor silences extrasynaptic utrophin by N-box mediated repression in skeletal muscle.Functional substitution by TAT-utrophin in dystrophin-deficient mice.Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel TherapiesDystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies.Serum Neuregulin-1beta as a Biomarker of Cardiovascular Fitness.A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation.Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx miceHigh throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomicsTargeting artificial transcription factors to the utrophin A promoter: effects on dystrophic pathology and muscle function.Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy.Neuregulin 1 Improves Glucose Tolerance in db/db MiceThe muscular dystrophies: from genes to therapies.Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advancesOverexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stagesTherapy insight: cardiovascular complications associated with muscular dystrophies.Emerging drugs for Duchenne muscular dystrophyCombinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy.Sarcospan: a small protein with large potential for Duchenne muscular dystrophy2015 William Allan Award.Neuregulin in cardiovascular development and diseaseOverexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type miceOverexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient miceThe synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.Identification of serum protein biomarkers for utrophin based DMD therapy.Progress in therapy for Duchenne muscular dystrophy.Cell-matrix interactions in muscle disease.Update on the treatment of Duchenne muscular dystrophy.Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening.What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.Overexpression of SERCA1a in the mdx diaphragm reduces susceptibility to contraction-induced damage.
P2860
Q24308714-5653B507-FA25-400D-9481-7595E241488FQ24601770-A79E4514-991F-4E66-9B74-88B11B531438Q28472887-11CB49C2-E6DC-41CF-B31A-E12E1555BB0FQ28477551-6C970FE4-2EB0-49F6-8D93-F6F3ECCE2F8CQ28478068-7AE0A7FF-C291-4496-81C7-196E5799E965Q28740842-7DBC7563-7632-4C09-814D-A37098BEB3D7Q33284878-FABC58C3-CE44-4889-AA3F-8A444EC24133Q33455443-5D888929-CCD0-4496-8024-BB0DF22789F0Q33608478-F6779D69-5320-45F1-9EE5-B019A88B916CQ33961107-2D02D114-0214-4CAE-BE48-3C2BFEE532F9Q33993588-00767C81-A85A-4534-A532-C96B81932E52Q34461955-FC4FADAF-956F-4181-A4B9-AD470971C306Q34490767-A7FA4285-5DB1-48B0-ABE5-4E659C5D55AAQ34792390-A5F7A210-D68B-4364-8740-B881C9F26827Q34863506-D290C9EE-99C9-43AE-8F81-05B94335B337Q34994545-BF75B8BE-E81B-41BB-BD00-11A9056EBAD2Q35720854-97821AC3-B4FC-45F6-A33A-7147DBE5382CQ35730880-2C23918A-B0DD-4EAB-90FB-F05A366BE852Q35834674-9087C297-B4E9-4445-8495-B3275DC57C35Q35847178-0E862152-2C3E-4478-A7E8-6B46DE3E3ECFQ35928246-906DFCE3-06CA-4C26-84A2-70C1E6F39A83Q36118063-8CF9EC02-4B8F-4664-9DB6-AD011A0BF603Q36304335-1DD24D5A-DA18-40DC-9394-70D55CF72C95Q36363716-189AB092-0AA7-49D9-AC77-A90B42634AD2Q36402509-8E61145F-2B42-4A8F-8028-C49B510056E6Q36414153-AF31FBCA-FF82-4DBC-AF2A-79884B024DDEQ36690397-592F7458-615C-4B6C-BB56-59C22D4D3658Q36707087-0BB6A949-B21C-4596-8CAE-CC37F9BA8C32Q37118330-8A9ECC22-ACF0-4CF3-AB24-06900DBC0DA7Q37139061-F79378F6-A099-418F-9633-ADDFA0FD2212Q37257159-545F753D-7C27-45A2-9C99-484D384B330AQ37361308-94B78A31-FDC7-4A66-B945-57FF3A7CCFDDQ37676311-A15FE728-E2AF-4F55-B4AC-E4DD70795177Q37908904-004A49DF-DD56-464A-BB14-DA87DFE89E28Q37944530-D173E51F-710D-4EA8-9B31-D5755C9F253BQ38074834-0D3CD4BA-CAE2-4CF0-A1FB-48DC68BADF31Q38087705-E9AD42AE-1CE4-4347-8EB0-EC7498BEFB7CQ38351283-A9B401B0-5ABD-472C-95F7-22F6E0AD4786Q38542416-329C1084-A40F-48AD-8FAB-31141C4C9D99Q41118342-506D47BE-2691-44F4-9CB8-583B27DBEE33
P2860
Heregulin ameliorates the dystrophic phenotype in mdx mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heregulin ameliorates the dystrophic phenotype in mdx mice.
@en
Heregulin ameliorates the dystrophic phenotype in mdx mice.
@nl
type
label
Heregulin ameliorates the dystrophic phenotype in mdx mice.
@en
Heregulin ameliorates the dystrophic phenotype in mdx mice.
@nl
prefLabel
Heregulin ameliorates the dystrophic phenotype in mdx mice.
@en
Heregulin ameliorates the dystrophic phenotype in mdx mice.
@nl
P2093
P2860
P356
P1476
Heregulin ameliorates the dystrophic phenotype in mdx mice.
@en
P2093
Alan W Flake
Claus J Jensen
Elisabeth H Javazon
Jacob Hansen-Schwartz
M Dominik Fischer
Sasha Bogdanovich
Tejvir S Khurana
Thomas O B Krag
P2860
P304
13856-13860
P356
10.1073/PNAS.0405972101
P407
P577
2004-09-13T00:00:00Z